Scientists shows AIDS vaccine candidate successfully 'primes' immune system

HIV
An HIV-infected cell. Credit: NIAID

New research led by scientists at The Scripps Research Institute (TSRI), International AIDS Vaccine Initiative (IAVI) and The Rockefeller University shows in mice that an experimental vaccine candidate designed at TSRI can stimulate the immune system activity necessary to stop HIV infection. The findings could provide key information for the development of an effective AIDS vaccine.

The research, published June 18, 2015 in concurrent studies in the journals Cell and Science, represents a leap forward in the effort to develop a against HIV, which has so far struggled to elicit antibodies ( molecules) that can effectively fight off different strains of the virus.

"The results are pretty spectacular," said Dennis Burton, chair of the TSRI Department of Immunology and Microbial Science and scientific director of two centers at TSRI, the IAVI Neutralizing Antibody Consortium (NAC) and the National Institutes of Health (NIH) Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID).

The Science study was co-led by Burton, TSRI Professor and IAVI NAC Associate Director of Vaccine Design William Schief, and TSRI Professor David Nemazee. The Cell study was co-led by Schief and Michel Nussenzweig, who is Zanvil A. Cohn and Ralph M. Steinman Professor at The Rockefeller University and a Howard Hughes Medical Institute (HHMI) investigator.

A Huge Challenge

The researchers' long-term goal is to design a vaccine that prompts the body to produce antibodies that bind to HIV and prevent infection.

While many vaccines for other diseases use a dead or inactive version of the disease-causing microbe itself to trigger antibody production, immunizations with "native" HIV proteins are ineffective in triggering an effective immune response, due to HIV's ability to evade detection from the immune system and mutate rapidly into new strains.

This challenge has led many researchers to believe that a successful AIDS vaccine will need to consist of a series of related, but slightly different proteins (immunogens) to train the body to produce broadly neutralizing antibodies against HIV—a twist on the traditional "booster" shot, where a person is exposed to the same immunogen multiple times.

In the new studies, the scientists tested one of these potential proteins, an immunogen called eOD-GT8 60mer, a protein nanoparticle designed to bind and activate B cells needed to fight HIV. The eOD-GT8 60mer was developed in the Schief lab and tested in mouse models engineered by the Nemazee lab to produce antibodies that resemble human antibodies.

Using a technique called B cell sorting, the researchers showed that immunization with eOD-GT8 60mer produced antibody "precursors"—with some of the traits necessary to recognize and block HIV infection. This suggested that eOD-GT8 60mer could be a good candidate to serve as the first in a series of immunizations against HIV.

"The vaccine appears to work well in our mouse model to 'prime' the antibody response," added Nemazee.

In the Cell paper, researchers used the same eOD-GT8 60mer immunogen but used a slightly different . "The immunogen again launched the immune system in the right direction," said Schief.

A concurrent study also in Science (led by Professor John Moore of Weill Cornell Medical College and including contributions from Schief, Burton, TSRI Associate Professor Andrew Ward, Ian Wilson, who is Hansen Professor of Structural Biology and chair of the Department of Integrative Structural and Computational Biology at TSRI, and other researchers) showed engineered immunogens also triggered immune responses in rabbit models and non-human primate models.

Next Steps

With eOD-GT8 60mer in the running as a potential contributor to an HIV vaccine, the researchers are now investigating other immunogens that could work in conjunction with it.

Schief said the Nemazee lab's mouse models will be crucial resources for testing other engineered immunogens. He emphasized the importance of bringing different disciplines together to engineer mouse models, design antibodies and analyze results. "This was a beautiful collaboration of three labs at TSRI," said Schief.


Explore further

New vaccine-design approach targets HIV and other fast-mutating viruses

More information: Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen, Science, 2015. www.sciencemag.org/lookup/doi/ … 1126/science.aac5894
Journal information: Science , Cell

Citation: Scientists shows AIDS vaccine candidate successfully 'primes' immune system (2015, June 18) retrieved 24 June 2019 from https://medicalxpress.com/news/2015-06-scientists-aids-vaccine-candidate-successfully.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
231 shares

Feedback to editors

User comments

Jun 18, 2015
You see I have a hard time understanding the human trials of these things -- one trial is long term effects if any can be seen, another trial is what ? get vaccinated and copulate with someone with AIDS?? what is the next step... is it release to the public and see if the overall number of AIDS cases goes down?? How do you prove this? what is your double blind? Married couples with one infected partner and they stop using protection?

Jun 19, 2015
That will be a very promising vaccine for HIV carrier, as more and more people are infected with HIV by various ways. Such vaccine can reduce the chance of HIV infection under the condition people have no idea how to protect themselves from it. BOC Sciences ( a biochemical provider) once published an article on the children friendly HIV drugs, helping to fill the treatment blank in children HIV.

Aug 14, 2015
It sounds that the HIV vaccine is on the process. Research of HIV antibody is always the hot of medicine for if it succeed, a large number of people will benefits from it.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more